GlassScriptPhysician profile
Peter J Armstrong
NPI 1942362942
$9,860.17
in general payments reported to CMS, 2019-2025
27 companies · $5,932 in 2025
The $5,932 reported for 2025 was more than what 86% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $684 · 2021: $192 · 2022: $134 · 2023: $257 · 2024: $2,384 · 2025: $5,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,403 · Food and Beverage: $3,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,402.54 |
| Food and Beverage | $3,170.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $4,640.94 | 2024-2025 | Indigo System |
| Abbott Laboratories | $2,643.20 | 2025 | Perclose Proglide, Esprit, Supera |
| Medtronic, INC. | $678.18 | 2021-2025 | Endurant Iis, Onyx Frontier |
| Endologix LLC | $662.33 | 2019-2020 | |
| Boston Scientific Corporation | $494.28 | 2020-2025 | Eluvia, Enroute Transcarotid Neuroprotection System, Watchman Flx |
| Janssen Pharmaceuticals, INC | $109.31 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.32 | 2023-2024 | Jardiance |
| Cardiva Medical, INC. | $83.12 | 2019-2024 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Shockwave Medical, INC | $66.57 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Silk Road Medical, INC. | $63.14 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Medtronic Vascular, INC. | $53.87 | 2019-2020 | |
| Organogenesis INC. | $27.45 | 2020 | |
| W. L. Gore & Associates, INC. | $25.92 | 2023 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Terumo Medical Corporation | $24.99 | 2019 | |
| Cardiovascular Systems INC. | $23.22 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $17.99 | 2023 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $17.86 | 2025 | Onpattro |
| Chiesi USA, INC. | $16.08 | 2025 | Kengreal |
| Smith+Nephew, INC. | $14.88 | 2019 | |
| Philips North America LLC | $14.70 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $14.59 | 2023 | Arcalyst |
| Atricure, INC. | $14.52 | 2024 | |
| United Therapeutics Corporation | $13.26 | 2024 | Tyvaso |
| La Jolla Pharmaceutical Company | $12.97 | 2023 | Giapreza |
| Daiichi Sankyo INC. | $12.90 | 2022 | |
| Guerbet LLC | $12.77 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.